Paragonix today announced a significant expansion of its GUARDIAN-Liver clinical registry with the appointment of a new principal investigator.
The Waltham, Massachusetts-based organ transplant technology developer — which Getinge acquired for $477 million last month — now has more than 500 enrollments in its clinical registry for its liver preservation and transport technologies. With this grwoth, the company named Dr. Kiran Dhanireddy as the study’s principal investigator. Dhanireddy serves as VP and chief of the Tampa General Hospital Transplant Institute.
Also the surgical director of the Comprehensive Liver Disease & Transplant Center, Dhanireddy has a deep clincial focus on liver transplantation and the surgical management of liver diseases. Paragonix says Dhanireddy brings “invaluable expertise” to the research efforts for the GUARDIAN registry.
As principal investigator, Dhanireddy leads and oversees the research team’s collective efforts within the registry.
“I’m honored to lead the GUARDIAN-Liver study as Principal Investigator, especially at this pivotal moment in liver transplantation where advancements in new technology are increasing the utilization of donor livers,” said Dhanireddy. “Expanding the donor pool and improving outcomes has long been a personal focus of mine, and I’m eager to explore the quantifiable impact of the LIVERguard system on transplant outcomes.
GUARDIAN-Liver focuses on the post-transplant outcomes in patients who received donor livers preserved and transported using the Paragonix LIVERguard Donor Liver Preservation System, as compared to traditional ice storage.
Paragonix expects to release the first report under Dhanireddy’s leadership in early 2025.
“The expansion of this registry marks a pivotal milestone for Paragonix as we continue to advance the science of liver preservation,” said Lisa Anderson, president of Paragonix. “This growth highlights our commitment to research and innovation, allowing us to continually explore and uncover the profound impact of our devices on transplant outcomes.”